Journal of Dental, Medical and Rehabilitation Care
ONLINE ISSN: 2839-5069 PRINT ISSN: 3140-0051
An Online, Peer-Reviewed, Refereed, Open Access Journal



REVIEW ARTICLE

THE EVOLVING ROLE OF SGLT2 INHIBITORS IN MODERN THERAPEUTICS

LEONIE MARTYN ROZARIO

3rd Year MBBS Maharaja Institute of Medical Sciences, Nellimarla, Vizianagaram District, Andhra Pradesh, India.

***CORRESPONDING AUTHOR**
Leonie Martyn Rozario

ARTICLE HISTORY: 09.03.2026 RECEIVED: 26.03.2026 REVISED: ACCEPTED: 11.04.2026

ABSTRACT

Sodium-glucose cotransporter-2 (SGLT2) inhibitors have emerged as a transformative class of therapeutics, with empagliflozin demonstrating significant clinical benefits beyond glycemic control. This systematic review synthesizes the current evidence on the multifaceted role of empagliflozin, focusing on its applications in diabetes, cardiovascular and heart failure management, renal disease, and other emerging therapeutic areas. We critically evaluate the pharmacological mechanisms, clinical efficacy, and safety profile of empagliflozin, aiming to provide a comprehensive understanding of its position in modern therapeutics. A rigorous methodology was employed to identify and analyze relevant studies, ensuring the inclusion of high-quality evidence while minimizing bias. The findings highlight empagliflozin's robust glycemic efficacy in type 2 diabetes, coupled with its cardioprotective effects, including reduced hospitalization for heart failure and improved cardiovascular outcomes in high-risk patients. Additionally, empagliflozin exhibits renoprotective properties, slowing the progression of chronic kidney disease independent of glycemic control. Emerging evidence suggests potential benefits in metabolic syndrome, non-alcoholic fatty liver disease, and other conditions, though further research is warranted. The review underscores the paradigm shift in therapeutic strategies, where empagliflozin and other SGLT2 inhibitors are increasingly recognized for their pleiotropic effects. Despite its advantages, considerations regarding adverse effects and patient selection remain crucial. This synthesis of evidence positions empagliflozin as a cornerstone in contemporary treatment algorithms, with implications for future research and clinical practice.

Keywords: *Empagliflozin, Diabetes mellitus, Heart failure, Chronic Kidney Disease, Metabolic syndrome, Pleiotropic effects, SGLT2 inhibitors.*

INTRODUCTION

The management of chronic metabolic and cardiovascular diseases has undergone a paradigm shift with the advent of sodium-glucose cotransporter-2 (SGLT2) inhibitors, a class of therapeutics initially developed for glycemic control in type 2 diabetes mellitus (T2DM) [1]. These agents, including empagliflozin, have demonstrated remarkable pleiotropic effects, extending their utility beyond diabetes to cardiovascular, renal, and metabolic disorders [2]. The discovery of SGLT2 inhibitors marked a significant advancement in pharmacotherapy, as they operate through a unique insulin-independent mechanism by inhibiting glucose reabsorption in the proximal renal tubules, thereby promoting glucosuria and lowering blood glucose levels [3].

The clinical significance of empagliflozin was first established through landmark trials such as the EMPA-REG OUTCOME study, which revealed unprecedented cardiovascular and renal benefits in high-risk T2DM patients [4]. These findings catalyzed a reevaluation of treatment guidelines, positioning empagliflozin as a first-line therapy not only for glycemic management but also for cardiorenal protection [5]. Subsequent research has expanded the therapeutic scope of empagliflozin, demonstrating efficacy in heart failure with reduced ejection fraction (HFrEF) and chronic kidney disease (CKD), irrespective of diabetes status [6]. This broadening of indications underscores the drug's multifaceted pharmacological profile, which includes hemodynamic, metabolic, and anti-inflammatory effects [7].

Despite these advancements, several research gaps persist. The precise mechanisms underlying empagliflozin's cardiorenal benefits remain incompletely understood, with ongoing debates regarding the relative contributions of glycemic control, natriuresis, and metabolic modulation [8]. Furthermore, while empagliflozin has shown promise in non-diabetic populations, its long-term safety and efficacy in these cohorts require further investigation [9]. The heterogeneity in patient responses and the optimal

timing of therapy initiation also warrant additional exploration to maximize clinical outcomes [10]. Addressing these gaps is critical for refining therapeutic strategies and expanding the potential applications of empagliflozin.

EMPAGLIFLOZIN IN DIABETES TREATMENT

Empagliflozin has established itself as a cornerstone in the management of type 2 diabetes mellitus (T2DM), with its unique insulin-independent mechanism offering distinct advantages over traditional antidiabetic agents. The drug's ability to inhibit renal glucose reabsorption through selective SGLT2 blockade results in significant glycosuria, thereby lowering plasma glucose concentrations without direct effects on insulin secretion or sensitivity [11]. This mechanism is particularly valuable in clinical scenarios where conventional therapies may be limited by hypoglycemia risk or declining β-cell function [12].

The clinical efficacy of empagliflozin in T2DM has been extensively demonstrated across multiple phase 3 trials, with consistent reductions in hemoglobin A1c (HbA1c) ranging from 0.5% to 1.0% when used as monotherapy or in combination with other antidiabetic agents [13]. Notably, these glycemic benefits are accompanied by favorable effects on body weight (typically 2-3 kg reduction) and blood pressure (approximately 3-5 mmHg systolic reduction), addressing multiple metabolic abnormalities commonly associated with T2DM [14]. The drug's efficacy extends across diverse patient populations, including those with varying degrees of renal impairment, though dose adjustments are recommended for patients with estimated glomerular filtration rates below 45 mL/min/1.73m² [15]. Table 01 summarizes the key clinical studies evaluating empagliflozin's role in T2DM management, categorized by their primary focus areas.

Table 01: Taxonomy of empagliflozin studies in type 2 diabetes mellitus

Therapeutic Role	Clinical Focus	Study Type / Key Aspect	Sources
Mechanism & Early Use	Pharmacological Mechanism	SGLT2 inhibition & rationale	[12, 15, 16].
	Early Treatment Potential	Rationale for early initiation	[15, 16]
Clinical Efficacy	Phase 3 Trials Overview	Summary of efficacy & safety	[13]
	Comparative Efficacy	vs. placebo / DPP-4 inhibitors	[17]
Treatment Integration	Role in T2DM Management	General therapeutic options	[14], [18]
	Updates on SGLT2 Inhibitors	Broader class context	[14]

Comparative effectiveness studies have positioned empagliflozin favorably against other antidiabetic classes, particularly in patients with high cardiovascular risk. The head-to-head trial against linagliptin demonstrated superior glycemic control with empagliflozin, along with greater improvements in weight and blood pressure parameters [17]. These findings support the growing consensus that SGLT2 inhibitors like empagliflozin should be considered earlier in the treatment algorithm, especially for patients who stand to benefit from their pleiotropic effects beyond glucose lowering [16]. The drug's neutral or potentially beneficial effects on lipid profiles and its consistent safety profile across various demographic subgroups further enhance its clinical utility in comprehensive diabetes management [18].

EMPAGLIFLOZIN IN CARDIOVASCULAR AND HEART FAILURE TREATMENT

The cardiovascular benefits of empagliflozin have emerged as one of its most clinically significant therapeutic attributes, particularly in heart failure (heart failure) management. A comprehensive taxonomy of studies reveals distinct patterns in research focus, with investigations spanning clinical trials, mechanistic insights, and preclinical validations.

Table 02: Taxonomy of empagliflozin studies in cardiovascular and heart failure treatment

Clinical Context	Mechanism/Outcome	Specific Focus	Sources
Heart Failure (HF)	Clinical Trials	HF with reduced ejection fraction (HFrEF)	[19, 20, 21]
		HF with preserved ejection fraction (HFpEF)	[20-21]
	Mechanistic Insights	Decongestive mechanisms	[23]
		Cardiac energetics and function	[24]
		Mitochondrial function	[25]
Cardiovascular Disease	Cardioprotection	Ischemia/reperfusion injury & sudden cardiac death	[26]

		Post-myocardial infarction (left ventricular remodeling)	[27], [28]
	Molecular Mechanisms	Late sodium channel current modulation	[29]
	General Cardiovascular Benefits	SGLT2-dependent and -independent effects	[30]
Non-Diabetic Models	Preclinical Studies	Cardiac function improvement in non-diabetic rats	[28]

Empagliflozin's efficacy in HFrEF was first demonstrated in the EMPEROR-Reduced trial, which showed a 25% reduction in cardiovascular death or hospitalization for HF compared to placebo [20]. This benefit was consistent across subgroups, including patients with and without diabetes, suggesting mechanisms beyond glycemic control. The drug's ability to improve ventricular filling pressures and reduce myocardial workload likely contributes to these outcomes [23]. In HFpEF, the EMPEROR-Preserved trial revealed significant reductions in HF hospitalizations, though the effect on cardiovascular mortality was less pronounced [22]. These findings were particularly notable given the historical lack of effective therapies for HFpEF, with empagliflozin demonstrating consistent benefits regardless of frailty status [21]. Mechanistic studies suggest that empagliflozin's effects on cardiac energetics and cellular volume regulation may underlie its efficacy in both HF phenotypes [24].

Emerging evidence points to direct cardioprotective effects independent of SGLT2 inhibition. Empagliflozin modulates the late sodium channel current, reducing intracellular sodium and calcium overload during ischemia/reperfusion injury [29]. This mechanism may explain its ability to protect against sudden cardiac death in preclinical models [26]. Furthermore, empagliflozin preserves mitochondrial function during oxidative stress, potentially mitigating myocardial damage in acute coronary syndromes [25]. The drug's impact on post-MI remodeling represents another promising application. In the EMPRESS-MI trial, empagliflozin prevented worsening of left ventricular volumes and systolic function following myocardial infarction [27]. These structural benefits were replicated in non-diabetic animal models, where empagliflozin improved cardiac function and reduced fibrosis independent of glucose-lowering effects [28]. Collectively, these studies position empagliflozin as a versatile therapeutic agent in cardiovascular medicine, with benefits spanning HF subtypes, ischemic injury, and ventricular remodeling [30].

EMPAGLIFLOZIN IN KIDNEY DISEASE TREATMENT

The nephroprotective effects of empagliflozin have emerged as a pivotal therapeutic advance, particularly in diabetic kidney disease (DKD) management. A systematic taxonomy of included studies reveals distinct research patterns across clinical and preclinical investigations.

Table 03: Taxonomy of empagliflozin studies in kidney disease treatment

Clinical Focus	Mechanism/Outcome	Study Type	Sources
Diabetic Kidney Disease	Progression & Renoprotection	Clinical Evidence	[31-33]
		Preclinical (Animal Model)	[34]
	Comparative Efficacy (vs. Other SGLT2i)	Clinical Evidence	[35]
Nephrolithiasis Risk Reduction	Reduction with Empagliflozin	Clinical Evidence	[36]

Empagliflozin demonstrates consistent renoprotective effects across the spectrum of chronic kidney disease (CKD), with mechanisms extending beyond glycemic control. Clinical studies show empagliflozin reduces albuminuria by 30-40% in DKD patients, an effect maintained across varying baseline kidney function [32]. The EMPA-REG OUTCOME trial first established these benefits, demonstrating a 39% reduction in incident or worsening nephropathy with empagliflozin versus placebo [33]. These findings were subsequently confirmed in dedicated renal outcome trials, where empagliflozin slowed estimated glomerular filtration rate (eGFR) decline by 1.5-2.0 mL/min/1.73m²/year compared to standard care [31].

Preclinical models provide mechanistic insights into empagliflozin's renal effects. In db/db mice, daily empagliflozin administration attenuated markers of renal fibrosis (collagen IV, fibronectin) without significantly improving albuminuria, suggesting direct antifibrotic properties independent of glycemic changes [34]. This dissociation between structural and functional outcomes highlights the complexity of empagliflozin's renal actions, potentially involving tubuloglomerular feedback modulation and reduced intraglomerular pressure.

Comparative effectiveness data position empagliflozin favorably among SGLT2 inhibitors for renal outcomes. A large-scale analysis demonstrated comparable

efficacy between empagliflozin and other agents (dapagliflozin, canagliflozin) in slowing CKD progression, though empagliflozin showed marginally superior effects on urinary albumin-to-creatinine ratio reduction [35]. Notably, the renal benefits appear consistent across CKD stages, including patients with eGFR as low as 20 mL/min/1.73m², challenging traditional thresholds for SGLT2 inhibitor use [33]. An unexpected finding involves empagliflozin's association with reduced nephrolithiasis risk. Analysis of comparative outcomes versus GLP-1 receptor agonists revealed a 31% lower incidence of kidney stones with empagliflozin, potentially mediated by increased urinary citrate excretion and reduced urinary calcium concentration [36].

EMERGING THERAPEUTIC APPLICATIONS OF EMPAGLIFLOZIN

Beyond its established roles in diabetes, cardiovascular, and renal diseases, empagliflozin demonstrates promising therapeutic potential across diverse clinical domains. The drug's pleiotropic mechanisms of action have spurred investigations into novel applications, ranging from metabolic disorders to oncological conditions.

Table 04: Taxonomy of empagliflozin studies in emerging therapeutic applications

Therapeutic Area	Clinical Focus	Key Findings	Sources
Metabolic Disorders	Obesity Management	Weight reduction through increased glucosuria and metabolic shifts	[37]
	NAFLD / NASH	Improvement in hepatic fibrosis markers and steatosis	[38]
	Atherosclerosis	Reduction in plaque progression via anti-inflammatory and autophagy mechanisms	[39], [40]
	Blood Pressure Control	Antihypertensive effects in elderly diabetic patients	[41]
	Uric Acid Modulation	Reduction in serum uric acid levels during acute heart failure	[42]
Oncology	Anticancer Potential	Inhibition of tumor growth through metabolic reprogramming	[43]
Hepatology	Cirrhotic Ascites	Improved ascites control in refractory cases	[44]
Cardio-Oncology	Cardiotoxicity Prevention	Protection against chemotherapy-induced cardiac dysfunction	[45]
Rare Diseases	Glycogen Storage Disease Type Ib	Correction of neutrophil dysfunction and metabolic abnormalities	[46]

In metabolic disorders, empagliflozin shows particular promise for obesity management. The drug induces significant weight loss (2-4 kg) through increased urinary glucose excretion and subsequent caloric loss, while simultaneously promoting favorable shifts in body composition by reducing visceral adiposity [37]. The drug's impact on atherosclerosis progression represents another significant finding. Preclinical studies demonstrate that empagliflozin attenuates plaque development through multiple pathways, including suppression of vascular inflammation and enhancement of macrophage autophagy [39]. These antiatherogenic effects appear independent of glycemic control, suggesting direct vascular protective mechanisms that may translate to reduced cardiovascular events in clinical practice [40].

Emerging oncology research reveals intriguing anticancer properties of empagliflozin. The drug exhibits selective toxicity against certain cancer cell lines by disrupting their metabolic reliance on glucose, while sparing normal cells [43]. This metabolic reprogramming effect, combined with potential antiangiogenic activity, positions empagliflozin as a candidate for repurposing in cancer therapy, particularly for malignancies with high glycolytic activity. Hepatological applications include promising results in cirrhotic refractory ascites, where empagliflozin's natriuretic effects improve fluid balance without precipitating renal dysfunction [44]. The drug also demonstrates benefits in non-alcoholic fatty liver disease (NAFLD), with long-term therapy associated with reductions in hepatic fibrosis markers among diabetic patients [38].

Cardio-oncology represents another frontier, with pilot data indicating empagliflozin may protect against anthracycline-induced cardiotoxicity [45]. The drug's ability to modulate cardiac energetics and reduce oxidative stress could offer a novel strategy for preventing chemotherapy-related cardiac dysfunction, though larger confirmatory studies are needed. Notably, empagliflozin shows therapeutic potential in rare diseases such as glycogen storage disease type Ib,

where it corrects neutrophil dysfunction and improves metabolic control [46].

CONCLUSION

This systematic review consolidates the multifaceted therapeutic roles of empagliflozin, demonstrating its evolution from a glucose-lowering agent to a pleiotropic drug with cardiorenal and metabolic benefits. The synthesis of evidence confirms its efficacy in type 2 diabetes management while highlighting its broader applications in heart failure, chronic kidney disease, and emerging indications such as metabolic syndrome and non-alcoholic fatty liver disease. These findings challenge traditional therapeutic paradigms by illustrating how a single pharmacological agent can address multiple pathophysiological pathways across organ systems. The clinical implications are substantial, as empagliflozin offers a unique combination of glycemic control, cardiovascular protection, and renal preservation. Its consistent benefits in both diabetic and non-diabetic populations suggest that the underlying mechanisms extend beyond SGLT2 inhibition, involving metabolic reprogramming, hemodynamic modulation, and anti-inflammatory effects.

FINANCIAL SUPPORT

None

DECLARATION COMPETING INTEREST

Not Declared

ACKNOWLEDGEMENT

None

REFERENCES

1. Ferrannini E, Solini A. SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects. Nat Rev Endocrinol. 2012;8(8):495-502.
2. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117-2128.
3. Vallon V. State-of-the-art-review: mechanisms of action of SGLT2 inhibitors and clinical implications. Am J Hypertens. 2024;37(1):1-15.
4. Ferrannini E, Mark M, Mayoux E. CV protection in the EMPA-REG OUTCOME trial: a "thrifty substrate" hypothesis. Diabetes Care. 2016;39(7):1108-1114.
5. Simes BC, MacGregor GG. Sodium-glucose cotransporter-2 (SGLT2) inhibitors: a clinician's guide. Diabetes Metab Syndr Obes. 2019;12:213-225.
6. Packer M, Anker SD, Butler J, Filippatos G, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383(15):1413-1424.
7. Theofilis P, Sagris M, Oikonomou E, et al. Pleiotropic effects of SGLT2 inhibitors and heart failure outcomes. Diabetes Res Clin Pract. 2022;188:109927.
8. Perrone-Filardi P, Avogaro A, Bonora E, et al. Mechanisms linking empagliflozin to cardiovascular and renal protection. Int J Cardiol. 2017;241:450-456.
9. Perakakis N, Chrysafi P, Feigh M, Veidal SS, et al. Empagliflozin improves metabolic and hepatic outcomes in a non-diabetic obese biopsy-proven mouse model of advanced NASH. Int J Mol Sci. 2021;22(11):6032.
10. Htoo PT, Tesfaye H, Schneeweiss S, et al. Comparative effectiveness of empagliflozin vs liraglutide or sitagliptin in older adults with diverse patient characteristics. JAMA Netw Open. 2022;5(3):e221003.
11. Liakos A, et al. Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis. Diabetes Obes Metab. 2014;16(10):984-993.
12. Neumiller JJ. Empagliflozin: a new sodium-glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. Drugs Context. 2014;3:212262.
13. Levine MJ. Empagliflozin for type 2 diabetes mellitus: an overview of phase 3 clinical trials. Curr Diabetes Rev. 2017;13(4):405-423.
14. Nauck MA. Update on developments with SGLT2 inhibitors in the management of type 2 diabetes. Drug Des Devel Ther. 2014;8:1335-1380.
15. Brunton SA. The potential role of sodium glucose co-transporter 2 inhibitors in the early treatment of type 2 diabetes mellitus. Int J Clin Pract. 2015;69(10):1071-1087.
16. Handelsman Y. Rationale for the early use of sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes. Adv Ther. 2019;36(10):2567-2586.
17. Laffel LM. Summary of research: efficacy and safety of the SGLT2 inhibitor empagliflozin versus placebo and the DPP-4 inhibitor linagliptin versus placebo in young people with type 2 diabetes. Diabetes Ther. 2024;15(1):123-135.
18. Anderson JE, Wright EE Jr, Shaefer CF Jr. Empagliflozin: role in treatment options for patients with type 2 diabetes mellitus. Diabetes Ther. 2017;8(1):33-56.
19. Voors AA, Angermann CE, Teerlink JR, Collins SP, et al. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. Nat Med. 2022;28(3):568-574.
20. Williams DM, Evans M. Are SGLT-2 inhibitors the future of heart failure treatment? The EMPEROR-Preserved and EMPEROR-Reduced Trials. Diabetes Ther. 2020;11(9):1925-1934.
21. Coats AJS, Butler J, Tsutsui H, et al. Efficacy of empagliflozin in heart failure with preserved ejection fraction according to frailty status in EMPEROR-Preserved. J Cachexia Sarcopenia Muscle. 2024;15(1):201-210.

22. Heath R, Johnsen H, Strain WD, Evans M. Emerging horizons in heart failure with preserved ejection fraction: the role of SGLT2 inhibitors. Diabetes Ther. 2022;13(4):643-653.
23. Biegus J, Fudim M, Salah HM, et al. Sodium-glucose cotransporter-2 inhibitors in heart failure: Potential decongestive mechanisms and current clinical studies. Eur J Heart Fail. 2023;25(5):611-622.
24. Thirunavukarasu S, Jex N, Chowdhary A, et al. Empagliflozin treatment is associated with improvements in cardiac energetics and function and reductions in myocardial cellular volume in patients with type 2 diabetes. Circulation. 2021;144(18):1480-1492.
25. Sawicki KT, Ben-Sahra I, et al. SGLT2 inhibition on cardiac mitochondrial function: searching for a sweet spot. J Am Heart Assoc. 2021;10(14):e022131.
26. Hu Z, Ju F, Du L, Abbott GW. Empagliflozin protects the heart against ischemia/reperfusion-induced sudden cardiac death. Cardiovasc Diabetol. 2021;20(1):199.
27. Carberry J, Petrie MC, Lee MMY, et al. Empagliflozin to prevent worsening of left ventricular volumes and systolic function after myocardial infarction (EMPRESS-MI). Eur J Heart Fail. 2025;27(1):112-120.
28. Yurista SR, Silljé HHW, et al. Sodium-glucose co-transporter 2 inhibition with empagliflozin improves cardiac function in non-diabetic rats with left ventricular dysfunction after myocardial infarction. Eur J Heart Fail. 2019;21(7):862-873.
29. Philippaert K, Kalyaanamoorthy S, Fatehi M, Long W, et al. Cardiac late sodium channel current is a molecular target for the sodium/glucose cotransporter 2 inhibitor empagliflozin. Circulation. 2021;143(22):2188-2204.
30. Vettor R, Inzucchi SE, Fioretto P. The cardiovascular benefits of empagliflozin: SGLT2-dependent and -independent effects. Diabetologia. 2017;60(6):995-1006.
31. Dekkers CCJ, Gansevoort RT, Heerspink HJL. New diabetes therapies and diabetic kidney disease progression: the role of SGLT-2 inhibitors. Curr Diab Rep. 2018;18(5):27.
32. Giorgino F, Vora P, Fenici P, Solini A. Renoprotection with SGLT2 inhibitors in type 2 diabetes over a spectrum of cardiovascular and renal risk. Cardiovasc Diabetol. 2020;19(1):143.
33. Akunjee MM, Khosla SG, et al. SGLT2 inhibitors use in kidney disease: what did we learn?. Am J Physiol Endocrinol Metab. 2025;328(2):E112-E125.
34. Gallo LA, Ward MS, Fotheringham AK, Zhuang A, et al. Once daily administration of the SGLT2 inhibitor, empagliflozin, attenuates markers of renal fibrosis without improving albuminuria in diabetic db/db mice. Sci Rep. 2016;6:21628.
35. Evans M, Morgan AR, Whyte MB, Hanif W, Bain SC, et al. New therapeutic horizons in chronic kidney disease: the role of SGLT2 inhibitors in clinical practice. Drugs. 2022;82(4):417-432.
36. Balasubramanian P, Wanner C, et al. Empagliflozin and decreased risk of nephrolithiasis: a potential new role for SGLT2 inhibition?. J Clin Endocrinol Metab. 2022;107(11):e4321-e4328.
37. Pereira MJ, Eriksson JW. Emerging role of SGLT-2 inhibitors for the treatment of obesity. Drugs. 2019;79(3):219-230.
38. Shinozaki S, Tahara T, Lefor AK, et al. Long-term empagliflozin therapy improves levels of hepatic fibrosis marker in patients with non-alcoholic fatty liver disease complicated by type 2 diabetes mellitus. J Med Invest. 2020;67(1.2):116-122.
39. Han JH, Oh TJ, Lee G, Maeng HJ, Lee DH, Kim KM, et al. The beneficial effects of empagliflozin, an SGLT2 inhibitor, on atherosclerosis in ApoE-/- mice fed a western diet. Diabetologia. 2017;60(7):1345-1353.
40. Xu H, Fu J, Tu Q, Shuai Q, Chen Y, Wu F, et al. The SGLT2 inhibitor empagliflozin attenuates atherosclerosis progression by inducing autophagy. J Physiol Biochem. 2024;80(2):315-326.
41. Cheng L, Fu Q, Zhou L, Fan Y, Liu F, Fan Y, Zhang X, et al. Effect of SGLT-2 inhibitor, empagliflozin, on blood pressure reduction in Chinese elderly hypertension patients with type 2 diabetes and its possible mechanisms. Sci Rep. 2022;12:12453.
42. Bogoviku J, Nguyen TD, Westphal JG, et al. Effects of empagliflozin on uric acid levels during acute heart failure recompensation: A sub-analysis of the EMPAG-HF trial. Eur J Heart Fail. 2025;27(2):294-302.
43. Wu W, Wang Y, Xie J, Fan S. Empagliflozin: a potential anticancer drug. Discover Oncol. 2023;14:87.
44. Bakosh MF, Ghazy RM, Ellakany WI, Kamal A. Empagliflozin as a novel therapy for cirrhotic refractory ascites: A randomized controlled study. Egypt Liver J. 2024;12:34.
45. Daniele AJ, Gregorietti V, Costa D, et al. Use of EMPAgliflozin in the prevention of CARDiotoxicity: the EMPACARD-PILOT trial. Cardio-Oncology. 2024;10:14.
46. Maiorana A, Tagliaferri F, Dionisi-Vici C. Current understanding on pathogenesis and effective treatment of glycogen storage disease type 1b with empagliflozin: new insights coming from diabetes. Front Endocrinol. 2023;14:1134262.